Challenges and Opportunities for Using Common PRO Measures in Comparative Effectiveness Research

Similar documents
PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES PROMIS SLEEP DISTURBANCE AND NEURO-QOL SLEEP DISTURBANCE

PROMIS ANXIETY AND KESSLER 6 MENTAL HEALTH SCALE PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES

Building a learning healthcare system for suicide prevention

PROMIS DEPRESSION AND CES-D

PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES

PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES

PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES PROMIS PEDIATRIC ANXIETY AND NEURO-QOL PEDIATRIC ANXIETY

PROMIS DEPRESSION AND NEURO-QOL DEPRESSION

PROMIS PAIN INTERFERENCE AND BRIEF PAIN INVENTORY INTERFERENCE

PROMIS ANXIETY AND MOOD AND ANXIETY SYMPTOM QUESTIONNAIRE PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES

PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES PROMIS GLOBAL HEALTH-PHYSICAL AND VR-12- PHYSICAL

PROSETTA STONE METHODOLOGY A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES

COGNITIVE FUNCTION. PROMIS Pediatric Item Bank v1.0 Cognitive Function PROMIS Pediatric Short Form v1.0 Cognitive Function 7a

PSYCHOLOGICAL STRESS EXPERIENCES

INTRODUCTION TO ASSESSMENT OPTIONS

MEANING AND PURPOSE. ADULT PEDIATRIC PARENT PROXY PROMIS Item Bank v1.0 Meaning and Purpose PROMIS Short Form v1.0 Meaning and Purpose 4a

FATIGUE. A brief guide to the PROMIS Fatigue instruments:

PROMIS Overview: Development of New Tools for Measuring Health-related Quality of Life and Related Outcomes in Patients with Chronic Diseases

Patient Reported Outcomes in Clinical Research. Overview 11/30/2015. Why measure patientreported

PHYSICAL STRESS EXPERIENCES

ABOUT PHYSICAL ACTIVITY

Using Performance and Outcome Measures for Enhancing the Quality of Behavioral Health Care Services

PAIN INTERFERENCE. ADULT ADULT CANCER PEDIATRIC PARENT PROXY PROMIS-Ca Bank v1.1 Pain Interference PROMIS-Ca Bank v1.0 Pain Interference*

RARE DISEASE WORKSHOP SERIES Improving the Clinical Development Process. Disclaimer:

Smoking Social Motivations

INTRODUCTION TO ASSESSMENT OPTIONS

ANXIETY. A brief guide to the PROMIS Anxiety instruments:

Utilizing the NIH Patient-Reported Outcomes Measurement Information System

emeasure Titles and Descriptions

Data and Safety Monitoring in Pragmatic Clinical Trials. Susan S. Ellenberg, PhD Greg Simon, MD, MPH Jeremy Sugarman, MD, MPH, MA

Engaging with the new EU regulatory landscape for medical devices. Challenges and opportunities

PROMIS Physical Function PROMIS Fatigue PROMIS Sleep-Related Impairment 3 Activities and Pain Impact Scale

ANXIETY A brief guide to the PROMIS Anxiety instruments:

Implementing PROMIS for Routine Screening in Ambulatory Cancer Care

GLOBAL HEALTH. PROMIS Pediatric Scale v1.0 Global Health 7 PROMIS Pediatric Scale v1.0 Global Health 7+2

PHYSICAL FUNCTION A brief guide to the PROMIS Physical Function instruments:

SLEEP DISTURBANCE ABOUT SLEEP DISTURBANCE INTRODUCTION TO ASSESSMENT OPTIONS. 6/27/2018 PROMIS Sleep Disturbance Page 1

ABOUT SMOKING NEGATIVE PSYCHOSOCIAL EXPECTANCIES

ABOUT SUBSTANCE USE INTRODUCTION TO ASSESSMENT OPTIONS SUBSTANCE USE. 2/26/2018 PROMIS Substance Use Page 1

DEVELOPING PROMs TO HAVE MORE IMPACT. Copyright 2015 by the International Consortium for Health Outcomes Measurement. All rights reserved.

PROMIS: What is it, Why Use it, and How to Advance the Mission of Integrative Oncology

GENERAL SELF-EFFICACY AND SELF-EFFICACY FOR MANAGING CHRONIC CONDITIONS

History and Current State of PROs. Disclosures

Completing the Circle: Novel Methods for using PRO Scores in Shared Decision- Making and Patient Self-Management.

Check. Change. Control. Connecting Communities and Care

Writing Committee. ACP Performance Measurement Committee Members*

Monthly Campaign Webinar. October 19, 2017

For more information: Quality of Life. World Health Organization Definition of Health

Module 1 Webinar Guest presenter: Dr. Kurt Kroenke

Methodological Considerations in Using Patient Reported Measures in Dialysis Clinics. Acknowledgements

Epidemiology of First-Episode Psychosis in large, integrated healthcare systems

What Does a PROMIS T-score Mean for Physical Function?

Qualitative Methods and Patient Reported Outcome Measures. Susan C Pitt, MD, MPHS Assistant Professor of Surgery University of Wisconsin

APPENDIX 11: CASE IDENTIFICATION STUDY CHARACTERISTICS AND RISK OF BIAS TABLES

Functional Status Assessment Measures using Patient-Reported Outcomes. Phyllis Torda July 2013

10/30/2013. Disclosures. Defining Flares in RA RA Flare Group

National Quality Forum. Patient Reported Outcomes (PROs) in Performance Measurement. Draft Report for Comment 10/24/12

PRO ASSESSMENT IN CANCER TRIALS. Emiliano Calvo, Anita Margulies, Eric Raymond, Ian Tannock, Nadia Harbeck and Lonneke van de Poll-Franse

2015 NAIIS Summit Quality Measures May 12, 2015

Universally-Relevant vs. Disease-Attributed Scales

Ware NIH Lecture Handouts

Sources of Comparability Between Probability Sample Estimates and Nonprobability Web Sample Estimates

Measuring Patient Health with PROMIS : Applications for Social Integration Research and Care

Quality ID #411 (NQF 0711): Depression Remission at Six Months National Quality Strategy Domain: Effective Clinical Care

10/22/2013. The Dartmouth Spine Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Pragmatic Trials: What the Heck Are They and Why Should You Care?

NQF Behavioral Health Project Phase II Submitted Measures

2) Percentage of adult patients (aged 18 years or older) with a diagnosis of major depression or dysthymia and an

Integrating Care for the Whole Person: Collaborative Teams for Behavioral Health and Medical Conditions

Population Health Metrics. Steven Teutsch, MD, MPH March 19, 2015

The Future of Measuring Patient-Reported Outcomes in Rheumatology

The Health of Gender Minorities. Mark A Schmidt, PhD, MPH HCSRN 2019 Annual Meeting April 9, 2019

An Evidence Based Treatment Approach for Older Adults. Helen Stewart, MSW, LCSW Michelle Bonadies, LCSW

Racial and Socioeconomic Disparities in Appendicitis

Real-world data in pragmatic trials

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD & Comorbidity (UH2 MH )

Bringing machine learning to the point of care to inform suicide prevention

Racial and Ethnic Inequalities in Dementia: What Can We Learn from a Healthcare System Cohort?

FOCUS: Fluoxetine Or Control Under Supervision Results. Martin Dennis on behalf of the FOCUS collaborators

LifeBridge Physician Network Care Path Depression, Substance Abuse June 26, 2015

Upledger CranioSacral Immersion Report for Dr. John E. Upledger Program for Military Post-Traumatic Stress

Contents. What is item analysis in general? Psy 427 Cal State Northridge Andrew Ainsworth, PhD

Distress Screening Playbook

Minnesota Statewide Quality Reporting and Measurement System (SQRMS)

Performance of PROMIS and Legacy Measures Among Advanced Breast Cancer Patients and Their Caregivers

Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention

Validating a computable phenotype: Should results change a trial s primary outcome?

The Brief Addiction Monitor (BAM): A Tool to Support Measurement-based Care for People with Substance Use Disorders

May 2016 CTC/OHIC Measure Specifications

Patient Reported Outcomes in Arthritis, TJR, and Physical Activity Research

A Randomized Controlled Trial of In-Person and Telephone Cognitive Behavioral Therapy for Major Depression after Traumatic Brain Injury

Measurement-based Scales in Major Depressive Disorder:

June 2015 MRC2.CORP.D.00030

Migrating from UDS 2.0 to UDS 3.0: Modern psychometric methods. Paul K. Crane, MD MPH Department of Medicine University of Washington

Patient Reported Outcomes (PROs) Tools for Measurement of Health Related Quality of Life

Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS to ASCQ-Me

Pragmatic Clinical Trials. Disclosure/Conflict of Interest. Learning Objectives 7/15/2015. Friedly: No disclosures

PATIENT REPORTED OUTCOMES

The Value of Providing Collaborative Care Models For Treating Employees with Depression

Learning Activities and Oversight: Case Studies from Kaiser Permanente

Transcription:

Challenges and Opportunities for Using Common PRO Measures in Comparative Effectiveness Research Greg Simon, MD, MPH Group Health Research Institute David Cella, PhD Northwestern University Reesa Laws, BS Kaiser Permanente Center for Health Research

History of measurement-based care for depression Nationally: 1990-2000: Effectiveness trials of collaborative care programs 2000-2005: Large-scale implementation trials In our health systems: 2000-2005: Guidelines recommend use of standard outcome measures (PHQ9) 2005-2010: Implementation of PHQ9 in EHRs 2010-2015: Implementation of standard care processes and monitoring/reporting performance

PHQ9 Depression Questionnaire 9-item self-report questionnaire Maps to DSM criteria for major depression Has become default standard in most large healthcare systems

Health system motivations for collecting PHQ data: Internal quality initiatives External quality metrics Purchaser & health plan wellness initiatives

MHRN Role in promoting measurement-based care: Producers (and promoters) of effectiveness evidence Content experts for guideline development Technical consultation regarding measure selection Technical assistance with reporting and analytics Highlighting health system performance in research presentations and publications PHQ definitely had momentum so we threw all of our weight behind it.

Health system data streams for PHQ data: Visit-based questionnaires Online portal questionnaires Health Risk Appraisal questionnaires

Sources of PHQ9 data in MHRN health systems

Data quality problems Variable (and unknown) conditions of administration Missing items Duplicate records Complementary records

Why bother with this messiness? In 6 MHRN health systems: Approximately 1.9 million observations for approximately 600,000 unique patients For free!

Use Cases Pragmatic trial of outreach to prevent suicide attempt Weekly extraction of PHQ9 data to identify outpatients at risk for suicide attempt Population-based suicide risk calculator Link PHQ9 data and other predictors to develop point-of-care risk prediction tool Racial and ethnic variation in depression care Examine racial and ethnic variation in treatment adherence and clinical effectiveness Personalized care for treatment-resistant depression Identify patterns of prior treatment response predicting response to nextstep treatment

New measurement domains: Alcohol use disorders Externalizing disorders in children Mania/mixed symptoms in bipolar disorder Attention deficit disorder in adults These are health system priorities, not ours.

Health system motivations: Internal quality initiatives External quality metrics Purchaser & health plan wellness initiatives Note: Research is not on this list! (We are a little tail on a very big dog!)

Common measures and common metrics to enable CER in everyday healthcare settings David Cella PhD Northwestern University

Goal: Conduct comparative effectiveness research using data collected by the health care system Depression as the use case

Current state: PHQ-9 is dominant measure We can call that a common measure, but Several large and small providers resist PHQ-9 Kaiser Northern Ca Cleveland Clinic Suicide question PHQ-8 Length (PHQ-2; PHQ-4) Long-term relevance (DSM 4 5?)

A solution PRO Rosetta Stone (PROsetta Stone ) links Patient- Reported Outcomes Measurement Information System (PROMIS) measures with other related legacy instruments PHQ-9 score linked to the PROMIS Depression measures using procedures based on item response theory (and equipercentile) methods (Choi et al) Cross-walk tables Allows PHQ-9 scores to be expressed as standardized T- score linked to the PROMIS metric. Psychol Assess 2014:26(2);513 527 www.prosettastone.org

PROsetta Stone A Rosetta Stone for Linking Patient- Reported Outcome Measures www.prosettastone.org USPHS Grant No. RC4 CA157236-01 17

Depression is One of the 83 Calibrated PROMIS Banks or Scales T Score Mean = 50 SD = 10 Referenced to the US general population Can administer as 4-10 item short forms or Computer Adaptive Testing (CAT) www.nihpromis.org

Raw Score to T-Score Conversion Table for PHQ-9 to PROMIS (IRT Fixed Parameter Calibration Linking) PHQ-9 Score PROMIS T-score SE 0 37.4 6.4 1 42.7 5.3 2 45.9 4.8 3 48.3 4.7 4 50.5 4.3 5 52.5 4.0 6 54.2 3.8 7 55.8 3.7 8 57.2 3.6 9 58.6 3.5 10 59.9 3.4 11 61.1 3.3 12 62.3 3.3 13 63.5 3.2 14 64.7 3.2 15 65.8 3.2 16 66.9 3.2 17 68.0 3.1 18 69.2 3.2 19 70.3 3.2 20 71.5 3.2 21 72.7 3.3 22 74.0 3.4 23 75.3 3.5 24 76.7 3.6

Raw Summed Score 0 10 20 30 40 50 60 CES-D PHQ-9 BDI-II 30 40 50 60 70 80 90 PROMIS Depression T-Score Choi et al, Psychological Assessment, 26(2): 513-527, 2014

Term PROM (Patient-Reported Outcome Measure) PRO-PM (Patient-reported Outcome Performance Measure) Definition PHQ-9, a standardized tool to assess depression Example: Percentage of patients with diagnosis of major depression or dysthymia and initial PHQ-9 score > 9 with a follow-up PHQ-9 score < 5 at 6 months (NQF #0711) NQF prefers that PRO-PMs NOT be tied exclusively to a single PROM Adapted from National Quality Forum

Test Drive: Cleveland Clinic Study (Katzan et al) To determine the group-level and patient-level concordance in performance of 2 depressionrelated PRO-PMs assessed using different depression PROMs: 1. Patient Health Questionnaire-9 (PHQ-9) 2. PROMIS Depression Short-Form (PROMIS SF) 3. PHQ-9 co-calibrated on the PROMIS metric (PHQ-9 PROMIS ).

Results PROM scores across levels of PHQ-9 PROMIS Depression ShortForm PHQ-9 cocalibrated on PROMIS Metric (PHQ-9 PROMIS ) PHQ-9 PHQ-9

Analytic Methods 1. Concordance calculations continued Depression thresholds were defined using crosswalk tables* Category Positive depression screen PHQ-9 T-scores PROMIS SF and PHQ-9 PROMIS > 9 > 59.9 Remission < 5 < 52.5 Progress towards remission 50% 50% of PHQ-9 equivalent * Per Choi et al, Psychol Assess 2014:26(2);513 527

N=5,376 Results Depression Diagnosis: Percentage of patients with depression at the time of initial assessment during the study period Group Level Patient Level PROM PHQ-9, median [IQR] PROMIS ShortForm Mean (SD) Depression Score Depression Threshold % Meeting Threshold Difference (PHQ-9 other PROM) Concordance for Depression 7 [3,12] PHQ9>9 35.1% - - - 52.7 (11.2) PROMIS >59.9* 26.5% 8.6% 82.5% (4734/5736) Kappa, 95% CI 0.593, (0.571, 0.616) PHQ-9 PROMIS Mean (SD) 55.3 (10.5) PROMIS >59.9* 32.1% 3.0% 95.6% (5486/5736) 0.902 (0.891, 0.914) *based upon cut-offs used by Choi

N=5,376 Results Depression Diagnosis: Percentage of patients with depression at the time of initial assessment during the study period Group Level Patient Level PROM PHQ-9, median [IQR] PROMIS ShortForm Mean (SD) Depression Score Depression Threshold % Meeting Threshold Difference (PHQ-9 other PROM) Concordance for Depression 7 [3,12] PHQ9>9 35.1% - - - 52.7 (11.2) PROMIS >59.9* 26.5% 8.6% 82.5% (4734/5736) Kappa, 95% CI 0.593, (0.571, 0.616) PHQ-9 PROMIS Mean (SD) 55.3 (10.5) PROMIS >59.9* 32.1% 3.0% 95.6% (5486/5736) 0.902 (0.891, 0.914) *based upon cut-offs used by Choi

N=5,376 Results Depression Diagnosis: Percentage of patients with depression at the time of initial assessment during the study period Group Level Patient Level PROM PHQ-9, median [IQR] PROMIS ShortForm Mean (SD) Depression Score Depression Threshold % Meeting Threshold Difference (PHQ-9 other PROM) Concordance for Depression 7 [3,12] PHQ9>9 35.1% - - - 52.7 (11.2) PROMIS >59.9* 26.5% 8.6% 82.5% (4734/5736) Kappa, 95% CI 0.593, (0.571, 0.616) PHQ-9 PROMIS Mean (SD) 55.3 (10.5) PROMIS >59.9* 32.1% 3.0% 95.6% (5486/5736) 0.902 (0.891, 0.914) *based upon cut-offs used by Choi

*includes only patients who had diagnosis of depression by both PHQ9 and relevant PROM Results Depression Remission: The percentage of patients with initial PHQ-9 score >9 who have a follow-up PHQ-9 score < 5 (based on NQF #0711) N = 701 Group Level Patient Level PROM PHQ-9 PROMIS ShortForm % Depression at Baseline (n) 41.5% (291) 35.2% (247) PHQ9 PROMIS 38.1% (267) % Depression Follow-up (n) 36.7% (257) 33.7% (236) 35.2% (247) Remission Rate (n) 6.5% (19/291) 5.7% (14/247) 6.7% (18/267) Difference (PHQ-9 - other PROM)* Concordance Depression remission* -- -- 0.8% -0.2% 92.9% [184 of 198] 98.5% [256 of 260] Kappa, 95% CI 0.186 (-0.077, 0.449) 0.881 (0.765, 0.996)

*includes only patients who had diagnosis of depression by both PHQ9 and relevant PROM Results Depression Remission: The percentage of patients with initial PHQ-9 score >9 who have a follow-up PHQ-9 score < 5 (based on NQF #0711) N = 701 Group Level Patient Level PROM PHQ-9 PROMIS ShortForm % Depression at Baseline (n) 41.5% (291) 35.2% (247) PHQ9 PROMIS 38.1% (267) % Depression Follow-up (n) 36.7% (257) 33.7% (236) 35.2% (247) Remission Rate (n) 6.5% (19/291) 5.7% (14/247) 6.7% (18/267) Difference (PHQ-9 - other PROM)* Concordance Depression remission* -- -- 0.8% -0.2% 92.9% [184 of 198] 98.5% [256 of 260] Kappa, 95% CI 0.186 (-0.077, 0.449) 0.881 (0.765, 0.996)

*includes only patients who had diagnosis of depression by both PHQ9 and relevant PROM Results Depression Remission: The percentage of patients with initial PHQ-9 score >9 who have a follow-up PHQ-9 score < 5 (based on NQF #0711) N = 701 Group Level Patient Level PROM PHQ-9 PROMIS ShortForm % Depression at Baseline (n) 41.5% (291) 35.2% (247) PHQ9 PROMIS 38.1% (267) % Depression Follow-up (n) 36.7% (257) 33.7% (236) 35.2% (247) Remission Rate (n) 6.5% (19/291) 5.7% (14/247) 6.7% (18/267) Difference (PHQ-9 - other PROM)* Concordance Depression remission* -- -- 0.8% -0.2% 92.9% [184 of 198] 98.5% [256 of 260] Kappa, 95% CI 0.186 (-0.077, 0.449) 0.881 (0.765, 0.996)

Results Progress towards Remission: The percentage of patients with initial PHQ-9 score >9 who have a follow-up PHQ-9 score that is reduced by > 50% (based on NQF #1885) N=701 Group Level Patient Level PROM % with Depression at Baseline, (n) % Progress towards Remission, (n) Difference (PHQ-9 - other PROM)* Concordance Progress toward remission* Kappa, 95% CI PHQ-9 41.5% (291) 14.8% (43/291) - - PROMIS ShortForm 35.2% (247) 15.8% (39/247) -1.0% 88.9% (176/198) PHQ9 PROMIS 38.1% (267) 15.7% (42/267) -0.9% 94.6% (246/260) 0.529 (0.357, 0.701) 0.797 (0.695, 0.900) *includes only patients who had diagnosis of depression by both PHQ9 and relevant PROM

Results Progress towards Remission: The percentage of patients with initial PHQ-9 score >9 who have a follow-up PHQ-9 score that is reduced by > 50% (based on NQF #1885) N=701 Group Level Patient Level PROM % with Depression at Baseline, (n) % Progress towards Remission, (n) Difference (PHQ-9 - other PROM)* Concordance Progress toward remission* Kappa, 95% CI PHQ-9 41.5% (291) 14.8% (43/291) - - PROMIS ShortForm 35.2% (247) 15.8% (39/247) -1.0% 88.9% (176/198) PHQ9 PROMIS 38.1% (267) 15.7% (42/267) -0.9% 94.6% (246/260) 0.529 (0.357, 0.701) 0.797 (0.695, 0.900) *includes only patients who had diagnosis of depression by both PHQ9 and relevant PROM

Results Progress towards Remission: The percentage of patients with initial PHQ-9 score >9 who have a follow-up PHQ-9 score that is reduced by > 50% (based on NQF #1885) N=701 Group Level Patient Level PROM % with Depression at Baseline, (n) % Progress towards Remission, (n) Difference (PHQ-9 - other PROM)* Concordance Progress toward remission* Kappa, 95% CI PHQ-9 41.5% (291) 14.8% (43/291) - - PROMIS ShortForm 35.2% (247) 15.8% (39/247) -1.0% 88.9% (176/198) PHQ9 PROMIS 38.1% (267) 15.7% (42/267) -0.9% 94.6% (246/260) 0.529 (0.357, 0.701) 0.797 (0.695, 0.900) *includes only patients who had diagnosis of depression by both PHQ9 and relevant PROM

Conclusion High concordance in performance at the group level for depression PRO-PMs measured using PHQ-9, PROMIS SF and PHQ-9 PROMIS. Findings support the ability to use linkage of scale scores to assess performance of PRO- PMs using different PROMs This can enable depression measures choice flexibility for the HCS, and enable CER